I am radiology resident give me Approach, Common questions of viva in presenting Long Case of Bronchogenic carcinoma starting from Chest X ray to CECT Thorax

Reading File

Finding Sources

Searching PubMed

"Lung Neoplasms"[MeSH Terms] AND "Tomography, X-Ray Computed"[MeSH Terms]

Searching the Web

ACR Appropriateness Criteria noninvasive clinical staging primary lung cancer CT chest 2025

Finding Sources

Reading Web Page

https://www.radiologyinfo.org/en/info/acs-noninvasive-stagin…

Reading File

Long-case presentation: suspected bronchogenic carcinoma

Use a fixed sequence. Your aim is to demonstrate:

You recognize the lesion and localize it.
You identify radiographic consequences and complications.
On CECT, you assess T, N, M, resectability, and the best biopsy target.
You suggest the next staging investigation, not just the diagnosis.

1. Chest radiograph approach

Start with a one-line presentation

“This is a PA chest radiograph, with/without a lateral view, of an adult patient. Film quality is adequate. There is a [right/left] [central/peripheral] opacity centered in the [upper/middle/lower] zone, likely representing a pulmonary mass. I will assess for lobar collapse, hilar or mediastinal nodal disease, pleural involvement, osseous destruction, and contralateral disease.”

Do not call every opacity “bronchogenic carcinoma” immediately. Say “a lung mass suspicious for primary bronchogenic malignancy” until CT confirms the anatomy and extent.

A. Check technical adequacy first

PA vs AP, erect vs supine
Rotation: medial clavicles equidistant from spinous processes
Inspiration: approximately 6 anterior ribs or 10 posterior ribs
Exposure/penetration
Include apices, costophrenic angles, chest wall, and visible bones
Compare with prior imaging, if available

Viva question

Why does the projection matter?
AP films magnify the heart and mediastinum, making hilar/mediastinal assessment less reliable. Supine films may conceal pleural effusion and pneumothorax.

B. Localize the opacity

State:

Side: right / left
Zone and lobe
Central / peripheral
Hilar / parahilar / intrapulmonary / pleural based
Size, margin, density, cavitation, calcification
Effect on adjacent structures

Silhouette sign examples

Lost border	Likely anatomical location
Right heart border	Right middle lobe
Left heart border	Lingula
Right hemidiaphragm	Right lower lobe
Left hemidiaphragm	Left lower lobe
Aortic knuckle	Left upper lobe
Descending aorta	Left lower lobe

Viva question

How do you differentiate a hilar mass from a parenchymal mass?
A hilar mass is centered at the hilum and may produce hilar enlargement or altered hilar contour. A parenchymal mass is usually eccentric to the hilum and may show air bronchograms, convergence of vessels, or a segmental/lobar relationship. CT is definitive.

2. Chest radiograph patterns suggestive of bronchogenic carcinoma

A. Direct tumor signs

Solitary pulmonary nodule or mass, especially if:
- Spiculated or irregular margins
- Lobulated contour
- Increasing size on serial films
- Upper-lobe location
- Cavitation with irregular thick wall, classically associated with squamous cell carcinoma
Central/hilar mass
Unilateral hilar enlargement
Mediastinal widening from nodal disease
Apical/superior sulcus mass

Viva question

Which calcification patterns favor benignity?
Diffuse, central, laminated, and “popcorn” calcification are more often benign. Eccentric or stippled calcification does not exclude malignancy.

Viva question

Can a normal chest radiograph exclude lung cancer?
No. Small lesions, hilar lesions, endobronchial tumors, and lesions concealed by the heart, diaphragm, or clavicle can be missed. CT is more sensitive. CT is also markedly more sensitive than radiography for small pulmonary nodules.
Murray & Nadel’s Textbook of Respiratory Medicine, p. 462.

B. Indirect signs of central bronchogenic carcinoma

These are especially high-yield in viva.

1. Lobar or whole-lung collapse

Look for:

Volume loss
Fissural displacement
Hilar displacement
Mediastinal/tracheal shift towards collapse
Elevated hemidiaphragm
Compensatory hyperinflation of remaining lobes
A central obstructing hilar mass

Important statement:

“An adult with unexplained lobar collapse, particularly recurrent or persistent collapse, should be considered to have an obstructing endobronchial lesion until proved otherwise.”

A left upper lobe collapse due to a central tumor may show a veil-like left upper-zone opacity, ipsilateral tracheal deviation, and hyperexpansion of the left lower lobe. Goldman-Cecil Medicine, p. 920.

2. Golden S sign

Right upper lobe collapse plus a central hilar mass
The minor fissure assumes an S-shaped contour
Strongly suggests a central obstructing bronchogenic carcinoma, although other causes exist

3. Obstructive pneumonitis / nonresolving consolidation

Persistent focal consolidation despite appropriate treatment
Loss of volume or obstructed bronchus
May be due to an endobronchial tumor with post-obstructive infection

4. Unilateral hyperinflation

Partial bronchial obstruction causing check-valve phenomenon
Less common in adults, but may occur with endobronchial lesion

C. Signs of local extension or metastatic disease on radiograph

Pleural effusion, especially unilateral and recurrent
Pleural nodularity or circumferential pleural thickening
Rib destruction or extrapleural soft-tissue component: chest-wall invasion
Elevated hemidiaphragm: possible phrenic nerve involvement
Widened mediastinum: nodal enlargement or mediastinal invasion
Contralateral lung nodules
Vertebral, rib, clavicular, or scapular lytic lesions

Viva question

What does elevation of one hemidiaphragm indicate in lung cancer?
Possibilities include phrenic nerve palsy from mediastinal/hilar tumor or nodal disease, subpulmonic effusion, volume loss, or diaphragmatic involvement. Confirm with CT and, if needed, fluoroscopic sniff test or ultrasound.

3. Differential diagnosis of a mass-like opacity

State a short, logical differential, then explain why carcinoma is favored.

Peripheral mass

Primary bronchogenic carcinoma
Metastasis
Granuloma/tuberculoma
Rounded atelectasis
Fungal lesion
Hamartoma
Organizing pneumonia
Pulmonary arteriovenous malformation

Central/hilar mass

Primary lung carcinoma
Lymphoma
Metastatic lymphadenopathy
Tuberculous/sarcoid adenopathy
Vascular lesion, such as pulmonary artery enlargement or aneurysm

Viva question

How can rounded atelectasis mimic a tumor?
It produces a peripheral rounded mass, often in the lower lobe, with adjacent pleural disease and converging bronchovascular bundles, the “comet-tail” appearance on CT.

4. Transition from chest radiograph to CECT

Say this clearly:

“The radiograph demonstrates a suspicious [central/peripheral] pulmonary lesion with [collapse/effusion/hilar enlargement]. I would proceed to contrast-enhanced CT of the thorax, extending through the adrenal glands, to characterize the primary lesion, identify nodal and pleural disease, assess local invasion and resectability, detect intrathoracic metastases, and plan the safest high-yield tissue sampling route.”

CT with IV contrast is preferred for central tumors because it helps distinguish vessels from lymph nodes and delineates mediastinal invasion. Murray & Nadel’s Textbook of Respiratory Medicine, p. 1721.

5. CECT thorax: systematic reporting approach

Use this seven-part checklist every time.

1. Primary tumor: site and morphology

Describe:

Side and lobe
Central/endobronchial vs peripheral
Exact relationship to:
- Main bronchus
- Lobar bronchus
- Bronchus intermedius
- Carina/trachea
Maximum dimensions in three planes
Solid, cavitary, necrotic, or mixed attenuation
Margins: spiculated, lobulated, smooth
Enhancement and central necrosis
Airway narrowing, cut-off, encasement, or intraluminal component
Distal collapse, consolidation, mucus plugging, bronchiectasis, or air trapping
Satellite nodule(s)

Example

“There is a 5.4 × 4.8 × 4.6 cm heterogeneously enhancing, spiculated soft-tissue mass in the right upper lobe, extending to the right hilum and encasing the right upper-lobe bronchus, with abrupt bronchial cut-off and post-obstructive right upper-lobe collapse.”

2. T descriptor: assess local extent

In a viva, describe the finding first and then state its staging implication.

Look specifically for:

Size category
Visceral pleural involvement
Chest-wall invasion:
- Intercostal muscle invasion
- Rib erosion/destruction
- Extrapleural extension
Diaphragmatic invasion
Pericardial involvement
Phrenic nerve involvement
Mediastinal fat infiltration
Involvement of:
- Heart
- Aorta
- Superior vena cava
- Pulmonary artery/vein
- Esophagus
- Trachea
- Carina
- Recurrent laryngeal nerve
- Vertebral body/spinal canal
- Brachial plexus
Separate tumor nodule:
- Same lobe
- Different ipsilateral lobe
- Contralateral lung

CT signs that support invasion

Definite destruction of bone or vertebral body
Tumor encasement/narrowing of a vessel
Intraluminal vascular tumor
Loss of intervening fat plane
Broad contact with mediastinal structure
Direct extension into chest wall, mediastinum, or neural foramina

Caution in viva: loss of fat plane or contact alone is not definitive. CT is imperfect for mediastinal and chest-wall invasion. Definite vertebral destruction, encasement, and mediastinal fat infiltration are much stronger signs. Murray & Nadel’s Textbook of Respiratory Medicine, p. 463.

Viva question

When is MRI useful in bronchogenic carcinoma?
MRI is useful when CT is equivocal for superior sulcus tumor, brachial plexus involvement, neural foraminal/spinal canal extension, vertebral invasion, chest-wall invasion, and some mediastinal or vascular invasion. MRI is superior for assessing the brachial plexus, spinal cord, and neural foramina.

3. N descriptor: nodal assessment

Evaluate nodes by IASLC nodal station, not simply “mediastinal nodes.”

Nodal stations to mention

N1: ipsilateral peribronchial, hilar, intrapulmonary nodes
N2: ipsilateral mediastinal and subcarinal nodes
N3:
- Contralateral mediastinal nodes
- Contralateral hilar nodes
- Supraclavicular/scalene nodes on either side

CT nodal features

Short-axis diameter
Shape
Heterogeneity/necrosis
Loss of fatty hilum, where visible
Matting or extracapsular extension
Relationship to vessels and airways

Threshold

“A mediastinal node with short-axis diameter of 10 mm or more is morphologically suspicious on CT, but size is not equivalent to metastasis.”

CT criteria are limited. Some small nodes are malignant and many enlarged nodes are benign. Fishman reports up to 21% of nodes under 1 cm can be malignant and up to 40% of nodes above 1 cm benign. Fishman’s Pulmonary Diseases and Disorders, p. 561.

Viva question

What should be done with PET-positive mediastinal nodes?
They generally require tissue confirmation, commonly by EBUS-TBNA or EUS-FNA, before denying a potentially curative surgical option. Inflammatory and granulomatous disease may cause false-positive FDG uptake.

Viva question

Why cannot CT alone stage mediastinal nodes definitively?
CT relies chiefly on size. PET-CT improves functional assessment but still has false positives and false negatives. Pathologic confirmation is needed when nodal status changes management.

4. Pleura and pericardium

Look for:

Pleural effusion
Pleural nodules
Fissural nodularity
Diffuse/nodular pleural thickening
Chest-wall deposits
Pericardial effusion or nodularity

Viva question

What is the staging implication of malignant pleural or pericardial effusion?
It constitutes metastatic disease, M1a, if malignant or unequivocally tumor-related. Cytology may be required if the imaging/clinical context is uncertain.

5. Lungs and airways

Look for:

Separate nodules in same lobe
Separate nodule in a different ipsilateral lobe
Contralateral pulmonary nodules
Lymphangitic carcinomatosis:
- Nodular interlobular septal thickening
- Peribronchovascular interstitial thickening
Post-obstructive collapse/consolidation
Endobronchial lesion
Contralateral emphysema or fibrosis, relevant to surgical fitness

Key staging principle

Finding	TNM implication
Separate tumor nodule in same lobe	T3
Separate tumor nodule in different ipsilateral lobe	T4
Contralateral pulmonary nodule	M1a
Pleural/pericardial nodules or malignant effusion	M1a

6. Extrathoracic findings within the CT coverage

Always evaluate:

Adrenal glands
Liver
Upper abdominal nodes
Bones: vertebrae, ribs, sternum, scapula
Lower neck/supraclavicular nodes, if included

Viva question

How do you characterize an adrenal lesion in a patient with lung carcinoma?
First assess noncontrast attenuation, washout CT or chemical-shift MRI if appropriate, FDG avidity on PET-CT, interval growth, and morphology. Do not label every adrenal nodule as metastasis. An indeterminate solitary adrenal lesion may need dedicated imaging or biopsy if it changes management.

7. Suggest the best tissue diagnosis route

This is a frequent finishing question.

Imaging finding	Likely preferred sampling method
Central mass/endobronchial lesion	Flexible bronchoscopy with endobronchial biopsy/brushings
Enlarged mediastinal/hilar nodes	EBUS-TBNA, with EUS-FNA for selected stations
Peripheral lesion without accessible nodes	CT-guided transthoracic biopsy
Pleural effusion/nodules	Pleural fluid cytology, image-guided pleural biopsy, or thoracoscopy
Accessible supraclavicular node	Ultrasound-guided FNAC/core biopsy
Distant metastatic lesion that establishes stage IV	Biopsy of the safest accessible metastasis

Viva principle:

“Biopsy the site that gives diagnosis and highest stage with the least risk.”

6. Sample CECT presentation

“CECT thorax shows a heterogeneously enhancing 6.2 cm left upper-lobe central mass with endobronchial extension into the left upper-lobe bronchus, causing left upper-lobe collapse. The lesion abuts the mediastinal pleura and partially encases the left pulmonary artery; there is no definite vascular luminal invasion. There are enlarged necrotic left hilar, subcarinal, and left lower paratracheal nodes. No contralateral mediastinal or supraclavicular adenopathy is seen. There is no pleural effusion, pleural nodularity, contralateral pulmonary nodule, adrenal mass, or destructive osseous lesion in the scanned volume. Findings are highly suspicious for primary bronchogenic carcinoma with ipsilateral hilar and mediastinal nodal metastases. I would recommend PET-CT for whole-body staging, MRI brain according to histology and clinical stage, and EBUS-TBNA of the subcarinal or paratracheal node for diagnosis and nodal staging.”

Do not overstate vascular or mediastinal invasion if only abutment is seen.

7. Common viva questions with short answers

1. What are the common radiographic presentations of bronchogenic carcinoma?

Peripheral solitary pulmonary nodule/mass, hilar mass, lobar collapse, nonresolving pneumonia, unilateral hilar enlargement, mediastinal widening, pleural effusion, rib destruction, or an apical/superior sulcus mass.

2. Which tumor commonly cavitates?

Squamous cell carcinoma is classically associated with cavitation, especially a thick-walled irregular cavity. Cavitation is not specific and can occur in infection or other tumors.

3. What is the Golden S sign?

An S-shaped configuration of the right minor fissure caused by right upper-lobe collapse combined with a central hilar mass. It suggests an obstructing central bronchogenic carcinoma.

4. What is the importance of a nonresolving pneumonia?

It may represent post-obstructive infection distal to an endobronchial malignancy. CT and bronchoscopy should be considered, particularly in older patients or smokers.

5. Why is contrast given for CT staging?

It differentiates vessels from nodes, identifies vascular encasement/invasion, improves assessment of centrally placed tumors and mediastinal involvement, and helps assess liver/adrenal lesions in the included upper abdomen.

6. Which CT finding suggests nodal metastasis?

Short-axis diameter 10 mm or more is suspicious, especially if rounded, necrotic, or conglomerate. It needs PET-CT correlation and often tissue confirmation.

7. Define N1, N2, N3 disease.

N1: ipsilateral peribronchial/hilar/intrapulmonary nodes.
N2: ipsilateral mediastinal/subcarinal nodes.
N3: contralateral mediastinal/hilar or supraclavicular/scalene nodes.

8. What imaging is used after CECT thorax for staging?

For NSCLC, FDG-PET/CT from skull base to mid-thigh and MRI brain with/without contrast are generally appropriate after initial chest CT, depending on clinical stage and intended treatment. ACR staging guidance also supports CT chest with IV contrast as initial staging imaging.

9. Why is MRI brain needed when PET-CT has been done?

FDG-PET is relatively insensitive for brain metastases because normal cerebral glucose uptake is high. Contrast-enhanced brain MRI is more sensitive.

10. What are the sites of common distant metastases?

Brain, bone, liver, adrenal glands, contralateral lung, and extrathoracic lymph nodes.

11. What makes a superior sulcus tumor important?

It may invade the chest wall, lower brachial plexus, sympathetic chain, vertebrae, neural foramina, and subclavian vessels. MRI is particularly valuable for local mapping.

12. What is Pancoast syndrome?

Shoulder/arm pain in a C8-T2 distribution, weakness/wasting of intrinsic hand muscles, and possibly Horner syndrome due to sympathetic chain involvement.

13. What is Horner syndrome?

Ptosis, miosis, and anhidrosis from cervical sympathetic chain involvement.

14. What is SVC syndrome on CT?

Mediastinal tumor/nodal mass causing SVC narrowing or occlusion, collateral venous channels, chest-wall/mediastinal venous engorgement, and sometimes upper-body edema clinically.

15. What is the significance of malignant pleural effusion?

M1a disease, hence stage IV metastatic disease in NSCLC staging.

16. Does chest-wall invasion always mean unresectable disease?

No. Selected chest-wall involvement can be surgically resectable with en bloc resection. Resectability is multidisciplinary and depends on complete resection feasibility, nodal status, physiological reserve, and metastatic disease.

17. Can CT reliably determine resectability?

CT is the main anatomical roadmap, but has limitations for microscopic invasion and nodal status. PET-CT, EBUS/EUS or mediastinoscopy, MRI in selected cases, and multidisciplinary review are required. CT’s central aim is to separate likely resectable from clearly unresectable disease. Murray & Nadel’s Textbook of Respiratory Medicine, p. 463.

18. What is the role of PET-CT?

It detects metabolically active nodal and distant disease, identifies an optimal biopsy target, and may prevent futile surgery. FDG uptake is not cancer-specific and should be interpreted with anatomic imaging and histology.

19. How do you distinguish tumor from collapsed lung on CT?

Enhancing central mass with airway obstruction, loss of normal bronchovascular pattern, and sometimes different enhancement pattern from atelectatic lung. Contrast CT, multiplanar imaging, PET-CT, and occasionally MRI can help.

20. What should your final radiology impression include?

Most likely diagnosis
Primary tumor site and size
Airway obstruction/collapse
Definite or suspected local invasion
Nodal stations and likely N stage
Pleural/pericardial involvement
Pulmonary and visible extrathoracic metastases
Provisional TNM stage, if appropriate
Best target and modality for tissue diagnosis
Recommended staging study, typically PET-CT and MRI brain where indicated

8. Last 30-second closing statement

“Overall, this is a [central/peripheral] lung mass highly suspicious for primary bronchogenic carcinoma, with [specific local extension], [specific nodal stations], and [presence/absence of pleural, contralateral pulmonary, adrenal, hepatic, or osseous metastatic disease]. The imaging should be correlated with PET-CT and histological confirmation. The most appropriate tissue target is [EBUS-accessible mediastinal node/endobronchial mass/peripheral mass/pleural lesion], as it provides diagnosis and staging with minimal risk.”

A recent imaging systematic review exists on CT techniques, but it does not alter this core CXR-to-contrast CT staging approach (PMID: 39842305).

This is a shared conversation. Sign in to Orris to start your own chat.